Decreased IDE and IGF2 expression but increased Aβ40 in the cerebral cortex of mouse pups by early life lead exposure

Brain Research Bulletin

Volumn 121, Issue , 2016, Pages 84-90

  Li, Ning ^a   Yang, Guojun ^b   Wang, Yueying ^a   Qiao, Mingwu ^a   Zhang, Pingan ^a   Shao, Jianfeng ^a   Yang, Guoyu ^a  

^a HENAN AGRICULTURAL UNIVERSITY   (China)

^b Henan Engineering College   (China)

Author keywords

Beta amyloid protein 40; Cerebral cortex; Insulin degrading enzyme; Insulin like growth factor 2; Lead; Learning and memory

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IGF2 PROTEIN, MOUSE; INSULINASE; LEAD; PEPTIDE FRAGMENT; SOMATOMEDIN B;

ANIMAL; BRAIN CORTEX; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; INBRED MOUSE STRAIN; LEARNING DISORDERS; METABOLISM; MOUSE; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE;

AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; INSULIN-LIKE GROWTH FACTOR II; INSULYSIN; LEAD; LEARNING DISORDERS; MICE; MICE, INBRED STRAINS; PEPTIDE FRAGMENTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84955259009     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2016.01.004     Document Type: Article

References (47)

1. Agis-Balboa R.C., Arcos-Diaz D., Wittnam J., Govindarajan N., Blom K., Burkhardt S., Haladyniak U., Agbemenyah H.Y., Zovoilis A., Salinas-Riester G., Opitz L., Sananbenesi F., Fischer A. A hippocampal insulin-growth factor 2 pathway regulates the extinction of fear memories. EMBO J. 2011, 30:4071-4083.
2. Alberini C.M., Chen D.Y. Memory enhancement: consolidation, reconsolidation and insulin-like growth factor 2. Trends Neurosci. 2012, 35:274-283.
3. Baranowska-Bosiacka I., Gutowska I., Rybicka M., Nowacki P., Chlubek D. Neurotoxicity of lead: hypothetical molecular mechanisms of synaptic function disorders. Neurol. Neurochir. Pol. 2012, 46:569-578.
4. Bueters T., von Euler M., Bendel O., von Euler G. Degeneration of newly formed CA1 neurons following global ischemia in the rat. Exp. Neurol. 2008, 209:114-124.
5. Bunn T.L., Parsons P.J., Kao E., Dietert R.R. Exposure to lead during critical windows of embryonic development: differential immunotoxic outcome based on stage of exposure and gender. Toxicol. Sci. 2001, 64:57-66.
6. Bassil N., Mollaei C. Alzheimer's dementia: a brief review. J. Med. Liban. 2012, 60:192-199.
7. Broughton S., Partridge L. Insulin/IGF-like signalling, the central nervous system and aging. Biochem. J. 2009, 418(1):1-12.
8. Canfield R.L., Henderson C.R., Cory-Slechta D.A., Cox C., Jusko T.A., Lanphear B.P. Intellectual impairment in children with blood lead concentrations below 10μg per deciliter. N. Engl. J. Med. 2003, 348:1517-1526.
9. Chao W., D'Amore P.A. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 2011, 19:111-120.
10. Charton J., Gauriot M., Guo Q., Hennuyer N., Marechal X., Dumont J., Hamdane M., Pottiez V., Landry V., Sperandio O., Flipo M., Buee L., Staels B., Leroux F., Tang W.J., Deprez B., Deprez-Poulain R. Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis. Eur. J. Med. Chem. 2014, 79:184-193.
11. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.W., Kovacina K.S., Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 2003, 162:313-319.
12. Costes S., Butler P.C. Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?. Cell Metab. 2014, 20(2):201-203.
13. Da Cruz Seabra J. Molecular dynamics simulations reveal a novel mechanism for ATP inhibition of insulin degrading enzyme. Chem. Inf. Model 2014, 54(5):1380-1390.
14. De Marco M., Halpern R., Barros H.M. Early behavioral effects of lead perinatal exposure in rat pups. Toxicology 2005, 211:49-58.
15. Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012, 13:225-239.
16. García-Lestón J., Roma-Torres J., Mayan O., Schroecksnadel S., Fuchs D., Moreira A.O., Pásaro E., Méndez J., Teixeira J.P., Laffon B. Assessment of immunotoxicity parameters in individuals occupationally exposed to lead. J. Toxicol. Environ. Health A 2012, 75:807-818.
17. Gilbert M.E., Lasley S.M. Developmental lead (Pb) exposure reduces the ability of the NMDA antagonist MK-801 to suppress long-term potentiation (LTP) in the rat dentate gyrus, in vivo. Neurotoxicol. Teratol. 2007, 29:385-393.
18. Gracia R.C., Snodgrass W.R. Lead toxicity and chelation therapy. Am. J. Health Syst. Pharm. 2007, 64:45-53.
19. Gu H., Wei X., Monnot A.D., Fontanilla C.V., Behl M., Farlow M.R., et al. Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neurosci. Lett. 2011, 490:16-20.
20. Hu Q., Fu H., Ren T., Wang S., Zhou W., Song H., Han Y., Dong S. Maternal low-level lead exposure reduces the expression of PSA-NCAM and the activity of sialyltransferase in the hippocampi of neonatal rat pups. Neurotoxicology 2008, 29:675-681.
21. Hrnkova M., Zilka N., Minichova Z., Koson P., Novak M. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 2007, 1130:206-213.
22. Jaako-Movits K., Zharkovsky T., Romantchik O., Jurgenson M., Merisalu E., Heidmets L.T., Zharkovsky A. Developmental lead exposure impairs contextual fear conditioning and reduces adult hippocampal neurogenesis in the rat brain. Int. J. Dev. Neurosci. 2005, 23:627-635.
23. Jiang C., Wang J., Li X., Liu C., Chen N., Hao Y. Progesterone exerts neuroprotective effects by inhibiting inflammatory response after stroke. Inflamm. Res. 2009, 58:619-624.
24. Lafuente J.V., Ortuzar N., Bengoetxea H., Bulnes S., Argandoña E.G. Vascular endothelial growth factor and other angioglioneurins: key molecules in brain development and restoration. Int. Rev. Neurobiol. 2012, 102:317-346.
25. Leal M.C., Fernandez Gamba A., Morelli L., Castaño E.M. Cerebral proteolysisof amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease. Medicina (B Aires) 2009, 69:466-472.
26. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
27. Liu M.C., Liu X.Q., Wang W., Shen X.F., Che H.L., Guo Y.Y., Zhao M.G., Chen J.Y., Luo W.J. Involvement of microglia activation in the lead induced long-term potentiation impairment. PLoS One 2012, 7:e43924.
28. Malito E., Hulse R.E., Tang W.J. Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 2008, 65:2574-2585.
29. Milekic M.H., Pollonini G., Alberini C.M. Temporal requirement of c/ebpbeta in the amygdale following reactivation but not acquisition of inhibitory avoidance. Learn. Mem. 2007, 14:504-511.
30. Milekic M.H., Alberini C.M. Temporally graded requirement for protein synthesis following memory reactivation. Neuron 2002, 36:521-525.
31. Miller B.C., Eckman E.A., Sambamurti K., Dobbs N., Chow K.M., Eckman C.B., Hersh L.B., Thiele D.L. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6221-6226.
32. Mukherjee A., Song E., Kihiko-Ehmann M., Goodman J.P., Pyrek J.S., Estus S., Hersh L.B. Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J. Neurosci. 2000, 20:8745-8749.
33. Nalivaeva N.N., Beckett C., Belyaev N.D., Turner A.J. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?. J. Neurochem. 2012, 120(Suppl. 1):167-185.
34. Nordin M., Bergman D., Halje M., Engström W., Ward A. Epigenetic regulation of the Igf2/H19 gene cluster. Cell Prolif. 2014, 47(3):189-199.
35. Li Ning, Yu Zengli, Wang Qi, Zheng Yantao, Jia Jinxia, Xinxin Liu N., Li Wenjie The effects of developmental lead (Pb) exposure on the expression of the CTGF and TGF-β1 in hippocampus of pups. Toxicol. Environ. Chem. 2009, 91:1375-1385.
36. O'Kusky J., Ye P. Neurodevelopmental effects of insulin-like growth factor signaling. Front. Neuroendocrinol. 2012, 33(3):230-251.
37. Pavelic K., Buković D., Pavelić J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol. Med. 2002, 8(12):771-780.
38. Perez A., Morelli L., Cresto J.C., Castano E.M. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 2000, 25:247-255.
39. Salazar-Ortiz J., Monget P., Guillaume D. The influence of nutrition on the insulin-like growth factor system and the concentrations of growth hormone, glucose, insulin, gonadotropins and progesterone in ovarian follicular fluid and plasma from adult female horses (Equus caballus). Reprod. Biol. Endocrinol. 2014, 12:72.
40. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7(1):63-80.
41. Hu Qiansheng, Fu Hongjun, Ren Tieling, Wang Shuyu, Zhou Wei, Song Hong, Han Yifan, Dong Shengzhang Maternal low-level lead exposure reduces the expression of PSA-NCAM and the activity of sialyltransferase in the hippocampi of neonatal rat pups. NeuroToxicology 2008, 29:675-681.
42. Prasanthi Rantham P.J., Reddy Gadi H., Reddy Gottipolu R. Calcium or zinc supplementation reduces lead toxicity: assessment of behavioral dysfunction in young and adult mice. Nutr. Res. 2006, 26:537-545.
43. Suresh C., Dennis A.O., Heinz J., Vemuri M.C., Chetty C.S. Melatonin protection against lead-induced changes in human neruoblastoma cell cultures. Int. J. Toxicol. 2006, 25:459-464.
44. Wen T., Liu Y.C., Yang H.W., Liu H.Y., Liu X.D., Wang G.J., Xie L. Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. J. Neurol. Sci. 2008, 270:99-106.
45. Zhang Xiao-yan, Liu Ai-Ping, Ruan Di-Yun Jin Liu Effect of developmental lead exposure on the expression of specific NMDA recep tor subunit mRNAs in the hippocampus of neonatal rats by digoxigenin-labeled in situ hybridizati on histochemistry. Neurotoxicol. Teratol. 2002, 24:149-160.
46. Yun S.W., Gärtner U., Arendt T., Hoyer S. Increase in vulnerability of middle-aged rat brain to lead by cerebral energy depletion. Brain Res. Bull. 2000, 52:371-378.
47. Wang Zhi-fei, Tang Li-li, Yan Han, Wang Yu-jun, Tang X. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol. Biochem. Behav. 2006, 83:603-611.